Jacobs Levy Equity Management’s VYNE Therapeutics VYNE Stock Holding History

Jacobs Levy Equity Management’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-11,272	Closed	-$1.28M	–	1124
2020 Q4	$1.28M	Buy	11,272 +5,469	+94%	+$687K	0.01%	665
2020 Q3	$694K	Buy	5,803 +2,501	+76%	+$292K	0.01%	726
2020 Q2	$411K	Buy	3,302 +2,617	+382%	+$354K	﹤0.01%	820
2020 Q1	$132K	Sell	685 -109	-14%	-$34.2K	﹤0.01%	938
2019 Q4	$265K	Sell	794 -212	-21%	-$70.7K	﹤0.01%	883
2019 Q3	$324K	Sell	1,006 -579	-37%	-$187K	﹤0.01%	769
2019 Q2	$684K	Buy	1,585 +128	+9%	+$63.3K	0.01%	696
2019 Q1	$823K	Buy	1,457 +113	+8%	+$54.2K	0.01%	702
2018 Q4	$399K	Buy	+1,344	New	+$602K	0.01%	773

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DAM

Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Jacobs Levy Equity Management's VYNE Position: Q1 2021 in Review

Jacobs Levy Equity Management sold out of VYNE Therapeutics (VYNE) in Q1 2021, closing a stake of 11,272 shares — an estimated $1.28M sold.

Jacobs Levy Equity Management first reported a position in VYNE in Q4 2018 and held it in 9 quarters. The position peaked at $1.28M in Q4 2020. 89 funds tracked by Wall St. Rank hold VYNE as of Q1 2021.

Jacobs Levy Equity Management reported no remaining VYNE Therapeutics position as of Q1 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 11,272 VYNE Therapeutics shares in Q1 2021, an estimated $1.28M.
Jacobs Levy Equity Management first reported a position in VYNE Therapeutics in Q4 2018 and held it in 9 quarters.
Jacobs Levy Equity Management's VYNE Therapeutics position peaked at $1.28M in Q4 2020.
89 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2021, filed 17 May 2021.